

The Top Line
Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning.
Episodes


How AI turns field conversations into actionable insights (Sponsored)

Use Kidney Genetics to Strengthen Clinical Trial Design (Sponsored)

GSK's double FDA win, Roche's $15B deal and the rise of point-of-care marketing

Inside Teva's Weltruza launch and Novo's GLP-1 strategy
Teva Pharmaceuticals recently secured FDA approval for Weltruza, a long-acting subcutaneous injectable treatment for schizophrenia designed to improve patient adherence by eliminating the need for loading doses or oral supplementation. This development marks a strategic shift for Teva as it pivots toward innovative med...

[Sponsored] The Next Chapter for AI in Clinical Trials

How AI could improve clinical trial decision-making (Sponsored)

How we picked the Fierce 15

Locking in on pharma’s consumerization trend

Fierce Pharma Week: A look at the biggest trends, campaigns and conversations

Inside the growing world of biopharma prediction markets

Clinical trials reach a new automation inflection point (Sponsored)

The future of RAS inhibitors
The recent approval of Revolution Medicines’ RAS inhibitor for advanced pancreatic cancer marks a significant milestone in oncology, validating the RAS pathway as a viable therapeutic target. Verastem Oncology CEO Dan Paterson and Chief Scientific Officer Jonathan Pachter emphasize that while this breakthrough offers a...

The people who stayed with the problem

MrBeast, Snapchat, AI and more: Pharma marketing’s pulse check

What did we learn from Big Pharma’s Q2 results?
Big Pharma maintained robust financial performance throughout the second quarter, with nine of the top 25 drug makers achieving double-digit revenue growth despite looming patent cliffs and shifting regulatory environments. Pharmaceutical companies are moving beyond general AI hype, integrating specific productivity to...

A genomics library for the AI era
Regeneron Genetics Center (RGC) leverages a massive, longitudinal genomic dataset to drive drug discovery and validate therapeutic targets. By sequencing over 3 million individuals—with a goal of reaching 20 million—the center prioritizes data diversity, particularly among non-European populations, to mitigate scientif...

How consumerization is reshaping pharma marketing (Sponsored)
The consumerization of healthcare, accelerated by GLP-1 medications, AI, and telemedicine, is fundamentally reshaping how patients interact with the medical system. Rachel Stoll and Kevin Nalty from Princeton 10 highlight that patients now frequently utilize digital wellness tools and AI to research symptoms before con...

Novo Nordisk’s CFO on the oral Wegovy rollout and beyond
Novo Nordisk’s second-quarter earnings exceeded market expectations, prompting a significant increase in full-year guidance driven by robust volume growth in the GLP-1 franchise. CFO Karsten Munk Knudsen highlights that the European rollout of the oral Wegovy pill, particularly in the UK, is experiencing rapid uptake v...

The next frontier in patient support: Connected data, AI and personalized engagement (Sponsored)
Patient services in life sciences are evolving from fragmented, reactive data silos into connected, AI-driven ecosystems designed to improve therapy adherence and patient outcomes. Despite an abundance of data from hubs and specialty pharmacies, poor integration currently hampers decision quality, contributing to signi...
Follow this podcast in Podwise
Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.
